GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability
Citations Over TimeTop 10% of 2008 papers
Abstract
The neuronal GABAergic mechanisms that mediate the symptomatic beneficial effects elicited by a combination of antipsychotics with valproate (a histone deacetylase inhibitor) in the treatment of psychosis (expressed by schizophrenia or bipolar disorder patients) are unknown. This prompted us to investigate whether the beneficial action of this combination results from a modification of histone tail covalent esterification or is secondary to specific chromatin remodeling. The results suggest that clozapine, or sulpiride associated with valproate, by increasing DNA demethylation with an unknown mechanism, causes a chromatin remodeling that brings about a beneficial change in the epigenetic GABAergic dysfunction typical of schizophrenia and bipolar disorder patients.
Related Papers
- → How to identify and manage non-response to clozapine?(2019)9 cited
- → Rechallenge of clozapine in a patient with a history of clozapine-induced myocarditis(2020)2 cited
- A study of the stability of plasma clozapine concentration in patents taking clozapine chronically(2007)
- 重度の精神症状のために 6 ヵ月以上の入院を余儀なくされている統合失調症患者に対するclozapineの有用性研究(2020)